Advertisement
Advertisement
U.S. markets close in 3 hours 28 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Sage Therapeutics, Inc. (SAGE)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
39.75+2.26 (+6.03%)
As of 12:32PM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close37.49
Open38.16
Bid39.58 x 1000
Ask39.67 x 2200
Day's Range38.15 - 39.86
52 Week Range36.13 - 98.39
Volume153,214
Avg. Volume464,458
Market Cap2.342B
Beta (5Y Monthly)1.74
PE Ratio (TTM)3.60
EPS (TTM)11.06
Earnings DateFeb 22, 2022 - Feb 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est74.75
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
18% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for SAGE

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Sage Therapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 08/10/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    4 months agoArgus Research
View more
  • Zacks

    Sage (SAGE), Biogen (BIIB) Report Data on Depression Drug

    Sage Therapeutics (SAGE) and partner Biogen (BIIB) announce positive data from a cohort of an ongoing phase III study, currently evaluating their investigational major depressive disorder drug zuranolone.

  • Business Wire

    Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDD

    CAMBRIDGE, Mass., December 01, 2021--Sage Therapeutics, Inc. (Nasdaq: SAGE), and Biogen Inc. (Nasdaq: BIIB) today announced 12-month data for the cohort of patients (n=199), who received zuranolone 50 mg once nightly for 14-days as their initial dose in the ongoing Phase 3 open-label SHORELINE Study and had the opportunity to be followed for 12-months. The SHORELINE Study, part of the LANDSCAPE clinical program, was designed to naturalistically follow adult patients with major depressive disorde

  • Investopedia

    Top Stocks for December 2021

    The Russell 1000 Index is a market-capitalization-weighted index of the 1,000 largest publicly traded companies in the U.S. It represents approximately 92% of the total market capitalization of all listed stocks in the U.S. equity market. Value investing is a factor-based investing strategy that involves picking stocks that you believe are trading for less than what they are intrinsically worth, usually by measuring the ratio of the stock's price to one or more fundamental business metrics. Value investors believe that if a business is cheap compared to its intrinsic value, (as measured by its P/E ratio, in this case) the stock price may rise faster than that of others as the price comes back in line with the worth of the company.

Advertisement
Advertisement